The roles of intracellular protein-degradation pathways in neurodegeneration

Nature

Volumn 443, Issue 7113, 2006, Pages 780-786

  Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEGRADATION; DISEASES; DRUG THERAPY; PROTEINS; TOXICITY;

CYTOSOLIC PROTEINS; HUNTINGTON'S DISEASE; MACROAUTOPHAGY; PARKINSON'S DISEASE;

NEUROLOGY;

ADENOSINE TRIPHOSPHATE; COPPER ZINC SUPEROXIDE DISMUTASE; DYNACTIN; PROTEASOME; RAPAMYCIN; RNA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

DEGRADATION; DISEASE INCIDENCE; NEUROLOGY; PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; CELL AGING; ENZYME SUBSTRATE; EXCITOTOXICITY; EXPERIMENTAL MODEL; GENE MUTATION; HETEROZYGOSITY LOSS; HUNTINGTON CHOREA; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; UBIQUITINATION; UPREGULATION; WILD TYPE;

EID: 33750363298     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05291     Document Type: Review

References (76)

1. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
2. Ross, C. A. & Poirier, M. A. What is the role of protein aggregation in neurodegeneration? Nature Rev. Mol. Cell Biol. 6, 891-898 (2005).
3. Perutz, M. F. & Windle, A. H. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143-144 (2001).
4. Pangalos, M. N., Jacobsen, S. J. & Reinhart, P. H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the β-amyloid peptide. Biochem. Soc. Trans. 33, 553-558 (2005).
5. Wellington, C. L. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862-7872 (2002).
6. Luo, S., Vacher, C., Davies, J. E. & Rubinsztein, D. C. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J. Cell Biol. 169, 647-656 (2005).
7. Wellington, C. L. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167 (1998).
8. Ciechanover, A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66, S7-S19 (2006).
9. Richly, H. et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 120, 73-84 (2005).
10. Weihl, C. C., Dalal, S., Pestronk, A. & Hanson, P. I. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet. 15, 189-199 (2006).
11. Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117 (2002).
12. Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. α-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013 (2003).
13. Verhoef, L. G., Lindsten, K., Masucci, M. G. & Dantuma, N. P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11, 2689-2700 (2002).
14. Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N. & Goldberg, A. L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 14, 95-104 (2004).
15. Holmberg, C. I., Staniszewski, K. E., Mensah, K. N., Matouschek, A. & Morimoto, R. I. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J. 23, 4307-4318 (2004).
16. Yorimitsu, T. & Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 12, 1542-1552 (2005).
17. Shibata, M. et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J. Biol. Chem. 281, 14474-14485 (2006).
18. Iwata, A. et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl Acad. Sci. USA 102, 13135-13140 (2005).
19. Qin, Z. H. et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum. Mol. Genet. 12, 3231-3244 (2003).
20. Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433-442 (2006).
21. Ravikumar, B. et al. mTOR inhibition induces autophagy and reduces toxicity of the Huntington's disease mutation in Drosophila and mouse models. Nature Genet. 36, 585-595 (2004).
22. Komatsu, M. et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 169, 425-434 (2005).
23. Ravikumar, B. et al. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum. Mol. Genet. 12, 985-994 (2003).
24. Rideout, H., Lang-Rollin, I. & Stefanis, L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int. J. Biochem. Cell Biol. 36, 2551-2562 (2004).
25. Massey, A., Kiffin, R. & Cuervo, A. M. Pathophysiology of chaperone-mediated autophagy. Int. J. Biochem. Cell Biol. 36, 2420-2434 (2004).
26. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46 (2003).
27. Seo, H., Sonntag, K. C. & Isacson, O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 56, 319-328 (2004).
28. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
29. Bowman, A. B., Yoo, S. Y., Dantuma, N. P. & Zoghbi, H. Y. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with a degree of nuclear inclusion formation. Hum. Mol. Genet. 14, 679-691 (2005).
30. Diaz-Hernandez, M. et al. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 23, 11653-11661 (2003).
31. Sun, X. M. et al. Caspase activation inhibits proteasome function during apoptosis. Mol. Cell 14, 81-93 (2004).
32. Zhang, Y. et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359 (2000).
33. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
34. Imai, Y., Soda, M. & Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661-35664 (2000).
35. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
36. Moore, D. J., West, A. B., Dawson, V. L. & Dawson, T. M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87 (2005).
37. Healy, D. G. et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 59, 627-633 (2006).
38. Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. & Lansbury, P. T. The UCH-L1 gene encodes two opposing enzymatic activities that affect á-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218 (2002).
39. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nature Genet. 23, 47-51 (1999).
40. Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genet. 36, 377-381 (2004).
41. McNaught, K. S., Perl, D. P., Brownell, A. L. & Olanow, C. W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149-162 (2004).
42. Kuma, A. et al. The role of autophagy during the early neonatal starvation period. Nature 432, 1032-1036 (2004).
43. Boya, P. et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell Biol. 25, 1025-1040 (2005).
44. Ravikumar, B., Berger, Z., Vacher, C., O'Kane, C. J. & Rubinsztein, D. C. Rapamycin pretreatment protects against apoptosis. Hum. Mol. Genet. 15, 1209-1216 (2006).
45. Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880-884 (2006).
46. Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889 (2006).
47. Ravikumar, B. et al. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nature Genet. 37, 771-776 (2005).
48. Glued perturbs dynactin function and induces protein aggregation. J. Cell Biol. 172, 733-745 (2006).
49. Puls, I. et al. Mutant dynactin in motor neuron disease. Nature Genet. 33, 455-456 (2003).
50. Hafezparast, M. et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300, 808-812 (2003).
51. Kieran, D. et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 169, 561-567 (2005).
52. Ligon, L. A. et al. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport 16, 533-536 (2005).
53. Cuervo, A. M., Stefansi, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295 (2004).
54. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820-5825 (2005).
55. Rodriguez-Lebron, E. & Paulson, H. L. Allele-specific RNA interference for neurological disease. Gene. Ther. 13, 576-581 (2006).
56. Davies, J. E., Sarkar, S. & Rubinsztein, D. C. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 15, 23-31 (2006).
57. Sanchez, I., Mahlke, C. & Yuan, Y. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003).
58. Martin-Aparicio, E. et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21, 8772-8781 (2001).
59. Yamamoto, A., Cremona, M. L. & Rothman, J. E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. 172, 719-731 (2006).
60. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
61. Kiffin, R., Bandyopadhyay, U. & Cuervo, A. Oxidative stress and autophagy. Antioxid. Redox Signal. 8, 152-162 (2006).
62. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
63. Lee, V. W. & Chapman, J. R. Sirolimus: its role in nephrology. Nephrology (Carlton) 10, 606-614 (2005).
64. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335-348 (2004).
65. Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005).
66. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
67. Sarkar, S. et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111 (2005).
68. Murphy, M. P. How understanding the control of energy metabolism can help investigation of mitochondrial dysfunction, regulation and pharmacology. Biochim. Biophys. Acta 1504, 1-11 (2001).
69. Pyo, J. et al. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J. Biol. Chem. 280, 20722-20728 (2005).
70. Nasir, J. et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioural and morphological changes in heterozygotes. Cell 81, 811-823 (1995).
71. Zeitlin, S. et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homolog. Nature Genet. 11, 155-163 (1995).
72. Duyao, M. P. et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410 (1995).
73. Harper, P. S. Huntington's Disease 2nd edn (WB Saunders, London, 1996).
74. Rubinsztein, D. C. Lessons from animal models of Huntington's disease. Trends Genet. 18, 202-209 (2002).
75. Ordway, J. M. et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91, 753-763 (1997).
76. Cattaneo, E., Zuccato, C. & Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nature Rev. Neurosci. 6, 919-930 (2005).